Huynh Cao is an Oncology physician affiliated with Loma Linda University. OpenAlex indexes 57 publications with 746 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11234 Anderson St
Loma Linda, CA 923501716
Telephone
909-558-2262Registry record last updated 15 Oct 2024.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year20241 payment
- Novartis Pharmaceuticals CorporationProgram year20243 payments
- PFIZER INC.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
28.4%Serotonin-3 Receptor Antagonist10.7%Ondansetron Hcl84%Ondansetron Odt16%Part D<11 patientsCorticosteroid7.2%Prednisone100%Part D≥17 patients+ 3 more classes in this area
Cancer & immunology
21.5%Aromatase Inhibitor7.4%Anastrozole71%Exemestane29%Part D<11 patientsAndrogen Receptor Inhibitor4.3%Xtandi100%Part D<11 patients+ 4 more classes in this area
Nervous system
11.4%Gabapentinoids4.5%Gabapentin65%Pregabalin36%Part D<11 patientsOpioid Agonist4.5%Tramadol Hcl65%Hydromorphone Hcl36%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nutrient-gene therapy as a strategy to enhance CAR T cell function and overcome barriers in the tumor microenvironment
Journal of Translational Medicine
2025 - Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer
Experimental Hematology and Oncology
2025 - Discovery of NFκB2-Coordinated Dual Regulation of Mitochondrial and Nuclear Genomes Leads to an Effective Therapy for Acute Myeloid Leukemia
International Journal of Molecular Sciences
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gary Fraser, MD
Loma Linda University
Jeffrey Rosenfeld, MD
Loma Linda University
Richard Robison, MD
Loma Linda University
Howard Gimbel, MD
Loma Linda University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”